CCNY researchers demonstrate effectiveness of contrast agent Cytate in detectcing prostate cancer

NEW YORK, June 26, 2008 –Researchers at the Institute for Ultrafast Spectroscopy and Lasers (IUSL) at The City College of New York (CCNY) have conducted time-resolved fluorescence measurement and optical imaging studies that demonstrate the efficacy of Cytate as a fluorescence marker to detect prostate cancer. Cytate, a contrast agent that conjugates to receptors on prostate cancer cells, exhibited greater fluorescence when applied to cancerous prostate tissue as opposed to normal prostate tissue.

Prostate cancer accounts for approximately 29 percent of cancer occurrences among men. According to "CA: A Cancer Journal for Clinicians," in 2007 it was responsible for 27,000 deaths in the United States. Early detection is important to reducing the death count.

Current noninvasive detection methods, which include digital exams, blood tests and ultrasound, have limited accuracy. "There is a need to develop a noninvasive technique for early detection of prostate cancer with higher accuracy and resolution," said Dr. Robert R. Alfano, Distinguished Professor of Science and Engineering and Director of IUSL.

Cytate is dye-peptide conjugate consisting of Indocyanine Green (ICG), an FDA-approved near-infrared dye, and a somatostatin receptor ligand. Somatostatin is a small cyclic neuropeptide that is believed to regulate the production of other hormones and perform an important role in the cancer development. Previous studies had shown that Cytate could target somatostatin receptor-rich pancreas tumors in animal model because of its high affinity for the receptors.

The researchers performed ultrafast time-resolved fluorescence polarization measurements on Cytate solution as well as on cancerous and normal prostate tissue sample that were stained with Cytate. In addition, they conducted fluorescence imaging of two small pieces of Cytate-stained normal and cancerous prostate tissue sandwiched between larger pieces of normal prostate tissue.

While the latter technique reveals which sections of tissue indicate presence of cancer, the former how the molecules of Cytate around the stained areas are behaving, explained Dr. Wubao Wang, a senior researcher at project leader at IUSL.

The time-resolved fluorescence polarization study found the ratio for peak fluorescence intensity between the cancerous and normal tissue was around 3.57.

"Somatostatin receptors are over-expressed on cancererous cells relative to normal cells, so they adsorb more of the Cytate," Professor Alfano added. "Cytate essentially is a smart reagent that attaches to cancerous cells. It is an excellent contrast agent because its absorption and fluorescence spectra line in the near-infrared 'tissue optical window (800 nanometers – 1 micron).'"

The next step in the investigation is development of an optical probe called the "photonic finger" that can perform imaging of the prostate from inside the body, he said. The project's ultimate goal is to develop reliable cancer detection techniques based on imaging as an alternative to biopsies.

The yet-to-be-developed probe unit was inspired by Dr. G. Nagamasu, a deceased urologist who was a personal friend of Professor Alfano. However, Professor Alfano added that before this can happen, a proven method needs to be developed for injecting Cytate into the patient.

The research was reported in Applied Optics, a journal published by the Optical Society of America, and was selected for publication in the most recent issue of the Virtual Journal for Biomedical Optics (VJBO) by the editor-in-chief, Gregory Faris.

It was supported by a grant from the U.S. Army Medical Research and Material Command. A new grant awarded to Dr. Wang is supporting development of the "photonic finger" near-infrared scanning polarization imaging unit. IUSL is seeking additional grants in biomedical optics to develop the compact unit and photonic explorers.

The research team: included Yang Pu, a Ph.D. candidate in electrical engineering; Dr. Wang; Dr. Bidyut Das, a scientist at IUSL; Dr. Samuel Achilefu, a researcher in the radiology department at Washington University School of Medicine, and Professor Alfano.

The Institute for Ultrafast Spectroscopy and Lasers (IUSL) of the City University of New York (CUNY) is a world-renowned multidisciplinary research laboratory in the Physics Departmentdevoted to promoting research and education in photonic and laser technologies for scientific, engineering, medical, and industrial applications.

Established in 1982 by Professor Robert R. Alfano, the IUSL has grown to encompass ten laboratories located in the Marshak Science Building of The City College of New York. Research and support staff now total 52. Among the major technical accomplishments are inventions of chromium-based Forsterite, Cunyite, and emerald lasers; fluorescence and excitation biopsy techniques for medical diagnostics; and optical biomedical imaging techniques. The IUSL researchers have published over 700 papers and have thus far been awarded more than 100 U.S. patents. The IUSL receives research grants from various federal and state agencies and industrial concerns. The research funding garnered by the IUSL has been over $3 million per year for the last 5 years. To date, 50 students, including seven female and five from underrepresented minority groups, have received their Ph.D. degrees in Physics, Chemical Engineering and Electrical Engineering conducting research at the IUSL laboratories.

For more than 160 years, The City College of New York has provided low-cost, high-quality education for New Yorkers in a wide variety of disciplines. Over 14,000 students pursue undergraduate and graduate degrees in the College of Liberal Arts and Sciences; The School of Architecture, Urban Design and Landscape Architecture (SAUDLA); The School of Education; The Grove School of Engineering, and The Sophie Davis School of Biomedical Education. For additional information, visit www.ccny.cuny.edu.